"Hypophosphatemia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A condition of an abnormally low level of PHOSPHATES in the blood.
| Descriptor ID |
D017674
|
| MeSH Number(s) |
C18.452.750.400
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hypophosphatemia".
Below are MeSH descriptors whose meaning is more specific than "Hypophosphatemia".
This graph shows the total number of publications written about "Hypophosphatemia" by people in this website by year, and whether "Hypophosphatemia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypophosphatemia" by people in Profiles.
-
Factors associated with phosphate homeostasis in children with beta-thalassemia major: An analytical cross sectional study from Pakistan. PLoS One. 2025; 20(2):e0316566.
-
Phosphorus levels in children treated with intravenous ferric carboxymaltose. Am J Hematol. 2021 06 01; 96(6):E215-E218.
-
The risk of refeeding syndrome among severely malnourished tuberculosis patients in Chhattisgarh, India. Indian J Tuberc. 2020 Apr; 67(2):152-158.
-
Tumor-induced Osteomalacia in a 3-Year-Old With Unresectable Central Giant Cell Lesions. J Pediatr Hematol Oncol. 2017 01; 39(1):e21-e24.
-
Exome sequencing identifies a novel homozygous mutation in the phosphate transporter SLC34A1 in hypophosphatemia and nephrocalcinosis. J Clin Endocrinol Metab. 2014 Nov; 99(11):E2451-6.
-
Should monitoring of fibroblast growth factor-23 levels in dialysis patients be a part of routine clinical practice? Semin Dial. 2014 Nov-Dec; 27(6):565-8.
-
Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum Mol Genet. 2014 Jan 15; 23(2):397-407.